Abstract
CD44 and RHAMM are two extracellar matrix receptors whose principle ligand is the polysaccharide hyaluronan (HA). Both proteins are involved in wound repair and their aberrant regulation contributes to a variety of diseases including arthritis and cancer. Over the past decade, a number of peptide-based therapeutics that block the binding of CD44 or RHAMM-specific ligands have been developed and tested in experimental models of disease. Here, we review the structure of each of these proteins, the functions they control and the mechanisms, including their interactions with each other, responsible for these functions. We also review the development of peptide mimics that block the key functions of CD44 and RHAMM and their use in experimental models of disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1775-1794 |
| Number of pages | 20 |
| Journal | Frontiers in Bioscience - Landmark |
| Volume | 17 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 Jan 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Arthritis
- CD44 peptides
- Peptide therapeutic potential
- Polysaccharide hyaluronan
- RHAMM peptides
- Review
Fingerprint
Dive into the research topics of 'RHAMM and CD44 peptides-analytic tools and potential drugs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver